Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 52 week low
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(178)
•••
Comment by Layth1990on Jul 17, 2021 7:18pm
150 Views
Post# 33565767

RE:RE:RE:52 week low

RE:RE:RE:52 week low

I have not voted before but i will definitly do it in augurst. I know 40k shares do not have a good voting power  but it is significant. Since last year he is ruining the company. We got into ph3 and we got a good deal. His financing strategy after nuance deal is sh*t play of the century. He sold tons of shares because he knows PH3 will get postponed. Not to mention he said there will be no dilution year ago and he diluted us twice. Where is nasdaq  and why reverse split? He is the worst ceo when it comes to schedule, was there anything on time ? No

I am pretty sure if dan is out, the company will do great. As long as he is the ceo it is a sinking ship because he ia greedy and knows nothing about investing. What type of ceo sells shares while the stock is sinking? He will probably buy when stock hits 2.5 and magically he will have money. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities